USA - NASDAQ:UBX - US91381U2006 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to UBX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-04-23 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | Chardan Capital | Initiate | Buy |
| 2024-08-22 | Rodman & Renshaw | Initiate | Buy |
| 2024-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-16 | Wedbush | Upgrade | Neutral -> Outperform |
| 2023-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-26 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-05-31 | Roth MKM | Initiate | Buy |
| 2023-05-26 | Citigroup | Maintains | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-25 | Wedbush | Maintains | Outperform |
| 2023-03-28 | Mizuho | Maintains | Buy |
| 2023-03-28 | Wedbush | Maintains | Outperform |
| 2023-03-28 | Citigroup | Maintains | Buy |
| 2023-03-28 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-16 | Wedbush | Reiterate | Outperform |
| 2023-03-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-16 | Mizuho | Maintains | Buy |
| 2022-11-09 | HC Wainwright & Co. | Maintains | Buy |
8 analysts have analysed UBX and the average price target is 3.06 USD. This implies a price increase of 1429.24% is expected in the next year compared to the current price of 0.2001.
The consensus rating for UNITY BIOTECHNOLOGY INC (UBX) is 77.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.